Brief: Kiniksa Pharma Reports Q3 2021 Financial Results And Recent Portfolio Execution

Kiniksa Pharmaceuticals International

01/11/2021 13:34

Nov 1 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA PHARMACEUTICALS REPORTS THIRD QUARTER 2021
FINANCIAL
RESULTS AND RECENT PORTFOLIO EXECUTION
    * Q3 REVENUE $12.1 MILLION
    * DATA FROM PHASE 3 TRIAL OF MAVRILIMUMAB IN
COVID-19-RELATED ARDS
EXPECTED IN Q1 2022
    * DATA FROM PHASE 2B TRIAL OF VIXARELIMAB IN PRURIGO
NODULARIS
EXPECTED IN 2H 2022
    * EXPECTS ARCALYST NET REVENUE FOR Q4 OF 2021 TO BE BETWEEN
$16.0
MILLION AND $17.0 MILLION
    * KINIKSA PHARMACEUTICALS - CONTINUES TO EXPECT ITS CASH,
CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS WILL FUND ITS CURRENT
OPERATING PLAN INTO 2023
    * QTRLY LOSS PER SHARE $0.44
    * Q3 EARNINGS PER SHARE VIEW $-0.65 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX9vlRln 
Further company coverage:  KNSA.O 

 ((Reuters.Briefs@thomsonreuters.com;;))